Gillen DL, Meyskens FL, Morgan TR, Zell JA, Carroll R, Benya R, Chen W-P, Mo A, Tucker C, Bhattacharya A, Huang Z, Arcilla M, Wong V, Chung J, Gonzalez R, Rodriguez LMaria, Szabo E, Rosenberg DW, Lipkin SM.
A phase IIa randomized, double-blind trial of erlotinib in inhibiting epidermal growth factor receptor signaling in aberrant crypt foci of the colorectum. Cancer Prev Res (Phila). 2015;8(3):222-30.
